A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?» Read More
About 12 million people claimed they were exempt from the law obligating they have health coverage.
Medicines in development at Biogen and Eli Lilly could be the first to slow the cognitive declines brought by Alzheimer’s disease. How do they work?
Timothy Walbert, Horizon Pharma chairman & CEO, talks about the company's earning providing patients access to drugs, and its bid for Depomed.
Discussing advancements in the effort to find a cure for Alzheimer's, with CNBC's Meg Tirrell and Fred Hassan, Warburg Pincus.
Biogen is looking to settle on one key thing: the perfect dose for its experimental Alzheimer's drug.
Aetna has severed ties with a agent who sold hundreds of heavily subsidized health plans to homeless people.
Most people want Medicare and Medicaid to keep their current structure, despite GOP calls for changes.
New seaweed strain has double the nutrients of kale, and tastes like bacon according to researchers.
Health plans sold on Obamacare exchanges on average have 34 percent fewer hospitals and doctors available than other options.
The Supreme Court’s ruling on Obamacare is a step in the wrong direction for the U.S. government, says this senator.
Existing anti-malaria drugs have the ability to treat Parkinson's disease, a team of international scientists announced on Thursday.
Marilyn Tavenner, who was in charge of HealthCare.gov's rollout, will head health insurance lobbying, The New York Times reports.
UnitedHealth may not be in the hunt to acquire a rival, but industry consolidation will be a big topic when it releases earnings.
Watch VitaPerk founder pitch his start-up in just 60 seconds to CNBC's "Power Pitch" panel.
Just a tiny number of clients of a tax audit defense company are being questioned about their Obamacare status.
Celgene announced Tuesday that it will acquire Receptos for $232 per share in cash for a total of about $7.2 billion.
Johnson & Johnson delivered quarterly earnings that topped analysts' expectations on Tuesday.
Newly eligible enrollees are costing an average of $5,517 per person, almost 20 percent above earlier estimates.
The FDA strengthens the warning on well-known pain relievers, but will it impact the big money behind those popular pills?
Jeb Bush won the tweet-off about American workers, says Larry Kudlow, and Hillary is just wrong.
Get the best of CNBC in your inbox